Introduction to Pd L1 Status
Sentence Examples
Discover more insights into Pd L1 Status
Keywords frequently search together with Pd L1 Status
Narrow sentence examples with built-in keyword filters
Pd L1 Status sentence examples within combined positive score
PD-L1 status was determined by combined positive score (CPS, number of PD-L1–staining cells [tumor cells, lymphocytes, macrophages] divided by the total number of viable tumor cells, multiplied by 100); PD-L1–positive was CPS ≥10.
Full Text
Pd L1 Status sentence examples within non small cell
PURPOSE/OBJECTIVE(S)
We hypothesized that FDG PET imaging during chemoradiation for unresectable non-small cell lung cancer (NSCLC) is prognostic for survival, and that PET response is correlated with systemic immune response to treatment, as characterized by peripheral immunologic correlates and tumor PD-L1 status.
Full Text
9046Background: The efficacy of immune checkpoint inhibitors (ICI) and PD-L1 status in patients with advanced non-small cell lung cancer (NSCLC) harboring oncogenic alterations has not been fully i.
Full Text
Pd L1 Status sentence examples within triple negative breast
BACKGROUND
Programmed-cell-death-ligand 1 (PD-L1) inhibitor treatment is approved for metastatic/recurrent, PD-L1 positive, triple-negative breast cancer (TNBC) and solid tumors with mismatch repair (MMR) defect regardless of PD-L1 status.
Full Text
Thus, despite the impressive results of immunotherapy of triple-negative breast cancer, there remains a fairly large group of patients with negative PD-L1 status, for whom it is necessary to develop other treatment strategies.
Full Text
Learn more from Pd L1 Status
The parameters, chosen by the experts, were performance status, International Metastatic renal cell carcinoma Database Consortium (IMDC) risk group, PD-L1 status, zugzwang and contraindication to immunotherapy.
Full Text
Stratification factors were tumour PD-L1 status, prior taxane, liver metastases and geographical region.
Full Text
Correlatives included tumor sequencing, PD-L1 status, and immunoprofiling.
Full Text
In early TNBC, pembrolizumab and atezolizumab have been tested in combination with standard neoadjuvant chemotherapy, resulting in a higher complete pathologic response rate than standard neoadjuvant chemotherapy alone, regardless of disease PD-L1 status.
Full Text
However, each assay has its own specific requirement of antibody clones, staining platforms, scoring algorithms, and cutoffs for the determination of PD-L1 status.
Full Text
PD-L1 status proved to be a significant factor for OS.
Full Text
Checkpoint inhibitor therapy may improve outcomes in soft tissue sarcoma regardless of PD-L1 status, especially when combined with cryoablation.
Full Text
Methods: Eligible pts with previously untreated unresectable stage III or IV melanoma were randomly assigned in a 1:1:1 ratio and stratified by PD-L1 status, BRAF mutation status, and metastasis stage.
Full Text
No differences in clinical outcome were found according to PD-L1 status or chemotherapy regimen chosen.
Full Text
Conclusions On the basis of this meta-analysis, the addition of a PD-1 inhibitor to first-line CT revealed statistically significant better outcomes and less additional toxicity compared with that of a PD-L1 inhibitor, as compared with CT alone, in advanced NSCLC, regardless of PD-L1 status.
Full Text
ORR was similar regardless of PD-L1 status ([TPS <1% and TPS ≥1%]; Cohort A, 66.
Full Text
Also molecular and immunohistochemical results such as PD-L1 status were only available on a limited number of patients.
Full Text
The measurement of serum exosomal PD-L1 as a quantitative factor with tumor PD-L1 status may help predict anti-PD-1 response and be used to assess clinical outcomes in patients with NSCLC.
Full Text
Correlative studies including PD-L1 status, WES and RNAseq are pending.
Full Text
Importantly, the DLS was indistinguishable from IHC-derived PD-L1 status in predicting PFS and OS, suggesting the utility of DLS as a surrogate for IHC.
Full Text
Conclusions PD-L1 status discordance in tumor cell occurs in approximately 20% of LCBM, with the greatest discordance in the <1% expression category.
Full Text
CONCLUSION
Intra-tumoral heterogeneity of PD-L1 expression may result in misclassification of PD-L1 status in a significant proportion of PD-L1 negative small biopsy samples.
Full Text
The aims of the present study were to classify primary BC cases based on the TIL levels and PD-L1 status, and to identify suppressive immune subsets in each categorized group.
Full Text
We further observed that sustained high NLR after initiation of treatment had a more profound impact on survival than baseline NLR, regardless of PD-L1 status.
Full Text
Selecting IBC patients by CD20 and PD-L1 status could stratify patients and potentially identify those in whom activating CD20 agents and anti-PD-1/PD-L1 therapy could be explored.
Full Text
PD-L1 status was available for 141 patients, and 75.
Full Text
In all patients with unknown PD-L1 status, maintenance avelumab plus BSC therapy guiding by PD-L1 expression testing (PD-L1-guided strategy) compared with the avelumab strategy and BSC strategy resulted in ICER of $105,360/QALY and $122,653/QALY, respectively.
Full Text
Conclusion
Detection of PD-L1 status by IHC enables identification of HNSCC patients eligible for future targeted immunotherapy.
Full Text
The PD-L1 status has no obvious connection with the efficacy of anti-PD-1 therapy.
Full Text
Efficacy outcomes appeared influenced by line of therapy and PD-L1 status.
Full Text
PD-L1 status was evaluated for all patients and only patients with PD-L1 expression ≥ 50% were included in the analysis.
Full Text
The addition of pembrolizumab and atezolizumab to neoadjuvant chemotherapy increased pathologic complete response rates, regardless of PD-L1 status, and event-free survival is pending.
Full Text
Therefore, HLA-B27 and HLA-B62 supertype may be used as adjunct biomarkers of response to anti-PD-1 therapy in patients with melanoma in addition to PD-L1 status, pending validation in prospective randomised clinical trials.
Full Text
Future studies are warranted to explore the prognostic value of categorizing patients based on TILs and PD-L1 status in different BC subtypes.
Full Text
MATERIALS AND METHODS
Immune-checkpoint inhibitor naive patients with advanced NSCLC (stage III/IV), irrespective of PD-L1 status, who had progressed after, or were refractory to first- or later-line therapy were enrolled and received cemiplimab 200 mg every 2 weeks intravenously for up to 48 weeks.
Full Text
It is not clear whether there is a difference in survival on first-line pembrolizumab for patients with a high PD-L1 status with or without a KRAS mutation.
Full Text
Pooled hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS) were included to assess the effects of PD-L1 status on the outcome of EGFR-TKI treatment and survival of EGFR-mutant NSCLCs.
Full Text
A stratification based on PD-1 and PD-L1 status was also significantly associated with overall survival (log rank P=0.
Full Text
The subjects were grouped according to histology, driver mutation status in the GTF2I gene, PD-L1 status, and smoking habits.
Full Text
In addition, we also conducted subgroup analysis on PFS, OS and ORR according to PD-L1 status.
Full Text
However, a LB at diagnosis is still not often used in clinical centers since a TB is currently the gold standard approach for histological diagnosis, assessment of the PD-L1 status on tumor cells and evaluation of the molecular alterations.
Full Text
Accordingly, clinical trials of combinatorial immuno-epigenetic drug regimens have been associated with tumor response in previously immunotherapy-resistant NSCLC patients irrespective of their PD-L1 status.
Full Text
Patients with recurrent/metastatic HNSCC or locally advanced/metastatic NSCLC naive to PD-1/PD-1-ligand inhibitors were enrolled; patients were not selected on the basis of oncogene driver mutations or PD-L1 status.
Full Text
These findings may support treatment decisions for patients with high PD-L1 status receiving first-line treatment for NSCLC.
Full Text
Methods: Pts aged ≥15 y with completely resected stage IIIB–C or IV melanoma stratified by stage and tumor PD-L1 status were randomized 1:1 to NIVO (3 mg/kg Q2W; n = 453) or IPI (10 mg/kg Q3W for 4 doses, Q12W thereafter; n = 453) for a maximum of 1 y or until disease recurrence/unacceptable toxicity.
Full Text
OBJECTIVE: To estimate the budget impact determined by the adoption of two different diagnostic strategies, SP142 assay or 22C3 assay, in the identification (in terms of PD-L1 status) of patients with mTNBC eligible for treatment with atezolizumab in combination with nab-paclitaxel.
Full Text
Electronic records were reviewed for age, histology, PD-L1 status, number of cycles of treatment, toxicities and scan results.
Full Text
Relevance with genomic transcriptome and mutation profile of PD-L1 status in EBVaGC was assessed with three datasets, the cancer genome atlas (TCGA), Gene Expression Omnibus (GEO) GSE51575, and GSE62254.
Full Text
Preliminary overall response rate (ORR) data from a multicenter phase 1b study (NCT03800836) evaluating a triplet combination of IPAT, atezolizumab, and taxane chemotherapy showed promising anti-tumor activity in a similar patient population, irrespective of PD-L1 status [Schmid, AACR 2019].
Full Text
BACKGROUND
Programmed-cell-death-ligand 1 (PD-L1) inhibitor treatment is approved for metastatic/recurrent, PD-L1 positive, triple-negative breast cancer (TNBC) and solid tumors with mismatch repair (MMR) defect regardless of PD-L1 status.
Full Text
In addition, predictive significance of PIOS score also persisted using a binary logistic regression analysis, adjusted for disease stage and PD-L1 status (p = 0.
Full Text
Unfortunately, the optimal platform to assess PD-L1 status is unknown, as it is the optimal cut-off value.
Full Text
PURPOSE/OBJECTIVE(S)
We hypothesized that FDG PET imaging during chemoradiation for unresectable non-small cell lung cancer (NSCLC) is prognostic for survival, and that PET response is correlated with systemic immune response to treatment, as characterized by peripheral immunologic correlates and tumor PD-L1 status.
Full Text
PD-L1 status was assessed with immunohistochemistry in tumor cells on tissue microarrays using clones 28-8, 22C3, SP263 and SP142.
Full Text
Patient and tumoral characteristics, including PD-L1 status (if available) and sequence of ICIs, were captured.
Full Text
Immuno-therapy (IO) response biomarkers: Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) and PD-L1 status were included.
Full Text
This should include appropriate patient selection and sequencing the therapy based on the available biomarkers such as PD-L1 Status.
Full Text
PD-L1 status was known for 21 of the 22 NSCLC (12 with ≥50% PD-L1 expression (DAKO 22C3).
Full Text
No relationship was found between incidence of ADA or baseline PD-L1 status and the efficacy endpoints PFS or OR.
Full Text
IMpassion031 showed improvements in pCR in eTNBC with neoadjuvant atezolizumab (A) plus nab-paclitaxel (nP) followed by A with doxorubicin/cyclophosphamide (AC) in patients (pts) with high-risk primary invasive eTNBC regardless of PD-L1 status (Mittendorf et al, Lancet 2020).
Full Text
Patient survival was predicted based on the PD-L1 status and CD8+ T-cell density.
Full Text
Atezolizumab is an anti-PD-L1 immune checkpoint inhibitor recommended for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy, regardless of PD-L1 status, among other treatment settings.
Full Text
Biomarkers of response to ICB, such as PD-L1 status, help identify suitable candidates for ICB.
Full Text
PD-L1 status was determined by combined positive score (CPS, number of PD-L1–staining cells [tumor cells, lymphocytes, macrophages] divided by the total number of viable tumor cells, multiplied by 100); PD-L1–positive was CPS ≥10.
Full Text
PD-L1 status alone cannot help guide treatment decision-making.
Full Text
Data further suggest tTMB is a significant and independent predictor beyond PD-L1 status.
Full Text
PD-L1 status was defined using the combined positive score (CPS).
Full Text
Analyses by PD-L1 status, age, ECOG performance status (PS) and renal impairment were prespecified; post hoc analyses explored outcomes by tumor location.
Full Text
On univariable and multivariable analysis, patient characteristics like age, sex, race, insurance, smoking status, performance status, and comorbidity score, as well as tumor characteristics like histology, EGFR status, and PD-L1 status, were not significantly associated with receipt of durvalumab.
Full Text
Background: In IMpassion031 (NCT03197935), patients (pts) (N = 333) with invasive stage II or III eTNBC who received NA treatment (tx) with atezolizumab (A) + nab-paclitaxel (nP) followed by doxorubicin + cyclophosphamide (AC; A-chemo) had significantly improved pathologic complete response (pCR, primary endpoint) regardless of PD-L1 status vs placebo (P) with nP and AC (P-chemo).
Full Text
Of 27 patients who had PD-L1 status tested, positive PD-L1 status did not significantly affect PFS (p = 0.
Full Text
5% had evaluable PD-L1 status.
Full Text
Are biopsies able to map the actual PD-L1 status of the entire tumor? Whole tumor slides of 56 gastric carcinoma were analyzed to determine the distribution of PD-L1 positive cells in the entire tumor areas.
Full Text